Trevi Therapeutics, Inc.

NASDAQ:TRVI

Biotechnology

Healthcare
$13.51 +2.63%

+$0.43 today

Market cap
$1.93B
Beta
1.05
P/E (TTM)
-53.6
EPS (TTM)
-$0.31
52W Low $5.41High $17.10

Volume 2.02M

Average 1.44M

TRVI Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Trevi Therapeutics, Inc.NASDAQ: TRVI

Selling, General & Admin · Q3 FY2026 · quarter ended Sep 2026

Selling, general & admin growth accelerates

Q3 FY2026 selling, general & admin of $5.42M rose 41.5% year over year, ahead of the +34.5% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 1.2% from the prior quarter. Over 3 fiscal years it compounded at +16.3% a year.

Context

  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 10 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +30.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
$5.42M+1.2% QoQ
Last fiscal yearDec 2025
$15.85M+30.5% YoY
LTMSep 2026
$19.78M+34.5% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+41.5%-100.0%-141.5 pp
1 year+30.5%-100.0%-130.5 pp
3-year CAGR+16.3%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
15.85M USD
Year-over-year change
+30.5%
4-year CAGR
+13.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How TRVI compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +34.5% is the 6th highest of 9, against a peer median of +38.3%.
  • Over three fiscal years its annual growth of +16.3% compares with a peer median of +59.9%.
TRVI Competitors
Selling, General & Admin for TRVI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ACADACADIA Pharmaceuticals Inc.LTM Sep 2026$646.09M USD+23.5%+14.1%53.7%
LQDALiquidia CorporationLTM Jun 2026$192.66M USD+74.7%+69.3%42.7%
VCREVicore Pharma Holding ABLTM Jun 2026SEK 48.85M SEK+20.6%+21.9%3673.4%
TBPHTheravance Biopharma, Inc.LTM Mar 2026$37.58M USD+103.1%+3.2%34.2%
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$34.94M USD-61.3%—50.2%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$34.27M USD+37.9%+181.0%171.4%
UPBUpstream Bio, Inc.LTM Mar 2026$27.71M USD+38.6%+59.9%834.2%
TENXTenax Therapeutics, Inc.LTM Mar 2026$23.09M USD+106.1%+61.1%—
TRVITrevi Therapeutics, Inc.LTM Sep 2026$19.78M USD+34.5%+16.3%—
Peer median (excluding TRVI) —+38.3%+59.9%53.7%

Competitors are the stored peer set for TRVI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development22.98M19.83M23.68M39.38M33.48M
Selling, General & Admin9.49M10.07M10.24M12.15M15.85M
Operating Expenses32.48M29.91M33.92M51.52M49.33M
Depreciation & Amortization50K43K123K147K144K
EBITDA(32.71M)(27.98M)(28.58M)(47.79M)(42.68M)
EBITDA Margin—————
Operating Income(32.48M)(29.91M)(33.92M)(51.52M)(49.33M)
Operating Margin—————
Interest Income10K1.74M4.75M3.6M6.54M
Interest Expense1.2M780K391K4K0
Other Income / Expenses(1.49M)719K4.83M3.58M6.51M
Income Before Tax(33.96M)(29.19M)(29.1M)(47.94M)(42.82M)
Pre-Tax Margin—————
Income Tax Expense(21K)(36K)(32K)(30K)(64K)
Net Income(33.94M)(29.15M)(29.07M)(47.91M)(42.76M)
Net Margin—————
EPS (Basic)(1.49)(0.45)(0.29)(0.47)(0.29)
EPS (Diluted)(1.49)(0.45)(0.29)(0.47)(0.29)
Weighted Avg Shares22.84M64.54M99.03M101.04M145.1M
Weighted Avg Shares (Diluted)22.84M64.54M99.03M101.04M145.1M

Trevi Therapeutics, Inc.

NASDAQ:TRVI

Intrinsic Alpha fair value

Locked

Current Price

$13.51

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.